Science4 distinct publishers3 min readUpdated
Arlotta's group at Harvard cultured cortical organoids past five years and got the gene activity of a 4-year-old. The model is longitudinal now, and priced in calendar years.
The Scientist · Science desk

Compiled by The ScientistSomething wrong?How this is made
Count from conception. A typical 4-year-old is roughly 57 months past that point, and the organoids whose gene activity matched that child had been in culture for about 60 [11][27]. Developmental time in the dish therefore ran at something close to 95 percent of wall-clock time [27]. The earlier checkpoints agree: at three to six months of culture the tissue looked like a fetal brain three to six months post-conception [10], and features that normally appear only after birth showed up at about a year [12]. Nothing in the data accelerates. Ten years of culture would buy about nine and a half years of development [28].
That is the number that prices every program built on this method. Arlotta's group says it is already using the organoids to screen for drugs that might alter the progression of conditions such as epilepsy [22], and a screen at a late-maturation phenotype means paying the years before the first dose.
It also sharpens a disagreement between the write-ups. Scientific American reports Madeline Lancaster of Cambridge, who was not involved, describing signs of maturation "and even aging like you see in an actual brain," with adult-onset disorders including schizophrenia, Alzheimer's and Parkinson's as the eventual payoff [23][19]. What was measured is a developmental trajectory in gene activity and DNA methylation that lands at age four [11][14]. A four-year-old cortex is not an aged one. Andras Lakatos, also at Cambridge and also uninvolved, puts it operationally: finding ways to speed up organoid ageing will matter [29], and his own disease examples, autism and epilepsy in later development, sit inside the window the tissue actually reached [20].
The cell-intrinsic result is the part that constrains the workaround. Dissociate an old organoid and the cells rebuild late-stage types; mix old cells with young ones and the old cells resume making neurons, but only the later-stage kinds [16]. Age travels with the cells rather than with the flask, so maturity cannot be borrowed by co-culture, and reseeding does not reset it.
Against the previous published ceiling of two years, reported in 2021, five analysed years is a 2.5-fold extension and the unanalysed seven-year cultures are 3.5-fold [7][26]. The enabling change was unglamorous: standard media did not sustain neuronal activity over long periods, and reformulating the medium to support spontaneous firing kept the populations alive, according to Noelia Anton-Bolanos, now at UMC Utrecht [8][9]. The seven-year cohort exists but is too small to analyse reliably [5]. STAT's account of the origin is telling on that point: the old organoids sat there until a junior scientist, Irene Faravelli, analysed them and then feared she had made a grave mistake [25]. Long culture was tolerated before it was designed for.
What the tissue still lacks bounds the claim in the other direction. There are no blood vessels, no large-scale neural architecture and no sensory input from a body, and Arlotta's own summary is that "at some point, you need much more" [17]. Cortical layering and vascularisation remain on the fix list [18]. On consciousness, Arlotta calls it highly unlikely that organoids are even faintly aware, while saying the question needs re-examining as the systems get more complex [24].
Follow any of these and your For You feed starts watching them — no settings page required.
Ranked by verification strength, evidence, and original report placement.
Cortical organoids grown for five years are the longest-lived brain organoids that have been studied in detail.
The team documented the organoids' progress over five years before submitting the research, then continued culturing some for two more years before ending the experiment.
Arlotta's team has grown the same kind of organoids for seven years, but there are too few of these older organoids to reliably analyse them.
Epigenetic changes accumulated in the organoids following the characteristic developmental pattern seen in the human brain, according to Anton-Bolanos.
The organoids' DNA accumulated chemical tags called methyl groups, which scientists often use to estimate a person's biological age.
The work is published in Nature as "Human brain organoids record the passage of time over multiple years."
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
Peer-reviewed, multi-modal, externally endorsed — but one lab and one cohort
The core result rests on a Nature paper with convergent readouts: cell-type sequence, gene expression, epigenetic marks and neuronal activity profiled at defined time points, benchmarked against previously recorded fetal brain measurements, plus a mechanistic dissociation and cell-mixing experiment. Two researchers uninvolved in the work independently endorse the ageing profile. Evidence stops short of high confidence because it is a single lab's cohort, the seven-year organoids are too few to analyse, and no external replication exists.
One lab, one pipeline; peers say they cannot readily follow
Every disclosed use sits inside the originating group — autism and epilepsy modelling plus epilepsy drug screening. An uninvolved expert states other groups will not readily be able to repeat multi-year culture because of expense and manual labour, and even the originating lab could not analyse its seven-year organoids. There is no second site, no commercial platform, no pricing and no licensing signal in these sources, so adoption is essentially a single-lab capability disclosure.
Headline framing outruns the measurement, though the caveats are printed
Sensing or recording time is a transcriptomic and epigenetic age correlation, yet one headline states the organoids 'can sense the passing of time' and another that they 'age like real brains' — language that invites more than the data show. The cluster's own derived pace figure of about 0.95 of wall-clock time is more precise than the coarse age anchors support, and a decade-scale extrapolation is contradicted by the senior author's own limit. The gap stays modest because all three substantive sources print the structural deficits, and Arlotta volunteers both the maturation ceiling and the consciousness caveat rather than hiding them.
Author-lab framing with a drug-screening stake, partly offset by two outside voices
Most forward-looking material is voiced by the study's own senior author and a co-author, and the lab discloses a drug-screening programme that benefits from the model being seen as a mature, disease-relevant platform; STAT's fuller account sits behind a subscription wall. Countervailing pressure is real: two researchers uninvolved in the work are quoted, one of them chiefly about cost, replication barriers and the need to accelerate ageing, and the senior author herself names the model's ceiling and the ethics question. No funding, sponsorship or vendor relationship is disclosed in these sources, so this is capped at moderate.
Facts well corroborated; pace arithmetic and diffusion are the soft spots
Four publishers on the same embargo, a named peer-reviewed paper, quantitative age anchors and two independent expert voices make the descriptive claims solid. Confidence is held below high because adoption evidence is single-lab, the seven-year window is unanalysed, the derived development-rate and ten-year projection are not supported at the stated precision, and the one paywalled source contributes only a provenance anecdote.
science
Brain organoids build the right cells in the wrong order, and that dents size-disorder models1 distinct publisher
science
A phage kinase with no target list: EMBL finds one enzyme that breaks several bacterial defences1 distinct publisher
science
HIPAA Covers Less Than You Think, And "Anonymized" Is Not A Legal Shield1 distinct publisher
product
LLNL closes a 20 percent gap in diamond melting, and stakes a fusion gain claim on it1 distinct publisher
Distinct publishers with included, body-backed reporting in this cluster.
1 article · August 21, 2026
1 article · August 19, 2026
1 article · August 19, 2026
1 article · August 19, 2026